treatment protocol to follow with drugs and dosage in detail for haemprotozoal disease in dogs and cats with sign symptoms

Reading File

Finding Sources

Searching the Web

haemoprotozoa dogs cats treatment protocol drugs dosage 2024 veterinary

Finding Sources

Reading Web Page

https://www.abcdcatsvets.org/guideline-for-babesiosis

Reading Web Page

https://www.merckvetmanual.com/generalized-conditions/ricket…

Searching PubMed

haemoprotozoa dogs cats treatment review

Searching Images

blood smear Babesia dog intraerythrocytic protozoa parasite

Table 2 (continued) <table><thead><tr><th>Disease</th><th>Causative organism</th><th>Distribution</th><th>Incubation</th><th>Clinical syndrome</th><th>Laboratory findings</th><th>Laboratory diagnosis</th><th>Treatment</th></tr></thead><tbody><tr><td colspan="8">Protozoan, viral, and other tick-borne illnesses</td></tr><tr><td>Protozoa Babesiosis</td><td>Babesia microti, Babesia spp.</td><td>Upper Midwest and Northeastern US</td><td>1–9 wk</td><td>- Fever, chills, sweats - Malaise, fatigue - Myalgia, arthralgia, headache - GI symptoms: anorexia, nausea, abdominal pain, vomiting - Dark urine - Less common: cough, sore throat, emotional lability, depression, photophobia, conjunctival injection - Mild splenomegaly, hepatomegaly, jaundice</td><td>- Decreased hematocrit - Thrombocytopenia - Elevated serum creatinine and BUN - Mildly elevated hepatic transaminases</td><td>- Identification of intraerythrocytic Babesia parasites on peripheral blood smear, or - PCR, or - Isolation of Babesia parasites from whole blood by animal inoculation Supportive criteria: - Babesia-specific antibody titer by IFA</td><td>Adults: - atovaquone 750 mg q 12 h AND azithromycin 500–1000 mg day 1, 150–1000 mg daily on subsequent days, 7–10 d Children: - clindamycin 300–600 mg IV q 6 h OR 600 mg po q 8 h AND quinine 650 mg po q 6–8 h, 7–10 d</td></tr><tr><td>Viruses Powassan virus disease</td><td>Powassan virus</td><td>Northeastern states and Great Lakes region</td><td>1–4 wk</td><td>- Fever, headache, vomiting, generalized weakness - Usually progresses to meningoencephalitis, may include meningeal signs, AMS, seizures, aphasia, paresis, movement disorders, cranial nerve palsies</td><td>- CSF: lymphocytic pleocytosis, mildly elevated protein, normal glucose</td><td>Virus-specific IgM antibodies in serum or CSF RT-PCR for viral RNA in acute CSF specimen or tissues</td><td>No specific antiviral treatment is available Supportive care</td></tr><tr><td>Colorado tick fever</td><td>Colorado tick fever virus</td><td>Western US, primarily CO, UT, MT, WY</td><td>1–14 d</td><td>- Fever, chills, headache, myalgias, lethargy - 50% have biphasic illness with symptoms remitting after 2–4 d, then recurring 1–3 d later - Conjunctival injection, pharyngeal erythema, lymphadenopathy - Maculopapular/Petechial rash in <20% - Prolonged convalescence with weakness and fatigue - DIC and meningoencephalitis is rare in children, can be fatal</td><td>- Leukopenia - Moderate thrombocytopenia</td><td>Culture and RT-PCR during first 2 wk of illness Serologic assays (IgM-capture EIA, IFA, plaque-reduction neutralization) on convalescent samples</td><td>No specific antiviral treatment is available Supportive care</td></tr><tr><td>Heartland virus disease</td><td>Heartland virus</td><td>Midwest, southern US</td><td>Unknown</td><td>- Fever - Fatigue - Decreased appetite - Headache - Arthralgia - Myalgia - Nausea - Diarrhea</td><td>- Leukopenia - Thrombocytopenia - Mild elevation in liver transaminases</td><td>Viral RNA and IgM/IgG antibodies</td><td>No specific antiviral treatment is available Supportive care</td></tr></tbody></table>

This composite image presents topographical and mechanical analyses of red blood cells (RBCs) infected with Babesia microti. Panels A-C show two-dimensional topographical height profiles. A healthy RBC (A) displays a characteristic biconcave discocyte shape with a central dimple. An infected Bm-RBC with parasite vacuoles (B) shows a loss of this central dimple and an irregular height profile, while an infected Bm-RBC without visible vacuoles (C) largely maintains the donut shape. Panels D-F depict dynamic membrane fluctuations measured by root-mean-square (RMS) height displacement. In panel E, arrows highlight high-value ring-shaped fluctuations surrounding the parasite vacuoles. The color scales indicate height (0-3 μm) and fluctuation (0-80 nm). Panel G is a scatter plot comparing membrane fluctuations (nm) among healthy RBCs, infected RBCs with vacuoles, and infected RBCs without vacuoles. The plot demonstrates that despite structural changes, the mechanical deformability of the host membrane remains statistically comparable across all three groups, a feature that distinguishes Babesia infection from Plasmodium-induced stiffening.

Summary : This figure shows two microscopy images (labeled C and D) of stained blood cells, highlighting the presence of small, dark-stained structures within or near the cells. photo: Scene Overview : • Two side-by-side light microscopy images of blood smears, labeled "C" (left) and "D" (right). • Main subjects are red blood cells with small, dark purple/blue-stained inclusions or organisms visible in the cytoplasm or adjacent to the cells. • Background is pale pink, typical of Giemsa or Wright’s stain. • The images are slightly out of focus, but the inclusions are clearly visible. Technical Details : • No visible scale bar or magnification indicator. • Staining method appears to be a standard hematological stain (e.g., Giemsa/Wright). • No on-image UI elements or additional text besides the labels "C" and "D" in the lower left and right corners, respectively. Spatial Relationships : • In image C, multiple inclusions are present within a single red blood cell, some connected by fine thread-like structures. • In image D, a single inclusion is seen near the edge of a red blood cell. • Both images focus on the central area of the field, with cells partially overlapping. Analysis : • The images likely compare two different morphological forms or stages of an intraerythrocytic organism (e.g., a blood parasite such as Plasmodium or Babesia). • Image C shows a more complex or segmented form, while image D shows a simpler, possibly single-nucleated form. • The visual differences suggest a comparison of developmental stages, species, or treatment effects on the organisms within red blood cells.

Now I have comprehensive data. Let me compile the complete, detailed treatment protocol.

Haemoprotozal Diseases in Dogs and Cats: Complete Treatment Protocol

Haemoprotozal (blood protozoan) diseases are caused by protozoan parasites that infect the blood cells or vascular tissues. The major ones affecting dogs and cats include Babesiosis, Ehrlichiosis/Anaplasmosis, Hepatozoonosis, Cytauxzoonosis (cats), Leishmaniosis, Trypanosomosis, and Haemoplasmosis (Mycoplasma haemofelis). Most are tick-transmitted, making vector control a cornerstone of prevention.

1. BABESIOSIS

Causative Agents

Dogs: Babesia canis (large Babesia - most common in Europe/Africa), Babesia gibsoni (small Babesia - SE Asia, USA), Babesia vulpes/B. microti-like (very small)
Cats: Babesia felis (South Africa), Babesia vogeli, Babesia clade VI

Signs and Symptoms

System	Clinical Signs
General	Fever (39.5-41°C), lethargy, anorexia, weakness
Haematological	Haemolytic anaemia, pale/icteric mucous membranes, thrombocytopaenia
Urinary	Haemoglobinuria ("red/brown urine"), bilirubinuria
GI	Vomiting, diarrhoea, hepatosplenomegaly
Neurological	Ataxia, seizures, "cerebral babesiosis" (B. canis)
Severe/Complicated	Acute kidney injury, ARDS, DIC, immune-mediated haemolytic anaemia (IMHA)

Treatment Protocol - DOGS

Drug	Dose	Route	Interval	Duration	Notes
Imidocarb dipropionate (drug of choice)	5-6 mg/kg	IM or SC	2 weeks apart (2 injections)	2 doses	Pre-treat with atropine (0.05 mg/kg SC) to prevent cholinergic side effects; effective for B. canis; less effective for B. gibsoni
Atovaquone + Azithromycin (for B. gibsoni/B. vulpes)	13.5 mg/kg + 10 mg/kg	PO with fatty meal + PO	q8h + q24h	10 days	Most effective for clearing parasitaemia (83% PCR-negative); expensive but best for B. gibsoni
Diminazene aceturate (not available in USA)	3.5 mg/kg (B. canis) / 5-7.5 mg/kg (B. gibsoni)	IM	Single dose / repeat q2 weeks x2-3	1-3 doses	Available in Asia, Africa, Europe; narrow therapeutic window
Phenamidine isethionate	15-16 mg/kg	SC	24h apart	2 doses	Alternative to imidocarb in some regions

Side effects of Imidocarb: Cholinergic signs - hypersalivation, lacrimation, tachycardia, dyspnoea, vomiting, diarrhoea. Always pre-medicate with atropine.

Treatment Protocol - CATS

Drug	Dose	Route	Interval	Duration	Notes
Primaquine phosphate (drug of choice - B. felis)	0.5 mg/kg	PO or IM	q72h x 1-3 doses, then weekly x 3 weeks	3-4 weeks total	Narrow therapeutic window - NEVER exceed 1 mg/kg (lethal); causes vomiting PO; monitor CBC and biochem weekly
Imidocarb dipropionate (B. vogeli, clade VI)	5 mg/kg	IM or SC	2 weeks apart	2 doses	Effective for non-B. felis species
Diminazene aceturate (B. vogeli, clade VI)	2-3 mg/kg	IM	Single dose	1 dose	Alternative for non-B. felis

Warning for cats: Most canine anti-Babesia drugs are ineffective or toxic in cats with B. felis. Primaquine is the only reliably effective drug for B. felis sensu stricto. Do not use buparvaquone, enrofloxacin, or danofloxacin - no anti-Babesia effect demonstrated.

Supportive Care (Both Species)

IV fluid therapy for dehydration/haemoglobinuria (Hartmann's solution or 0.9% NaCl)
Blood transfusion if PCV < 15% (dogs) or < 12% (cats)
Prednisolone 1-2 mg/kg/day PO if IMHA component confirmed
Monitor renal parameters, bilirubin, coagulation profile

2. EHRLICHIOSIS AND ANAPLASMOSIS

Causative Agents

Ehrlichia canis (Canine Monocytic Ehrlichiosis - CME) - most important; tick-borne (Rhipicephalus sanguineus)
Anaplasma phagocytophilum - dogs and cats; Ixodes ticks
Anaplasma platys (Canine Cyclic Thrombocytopaenia)
Ehrlichia ewingii - dogs only

Signs and Symptoms

Phase	Signs
Acute (1-4 weeks)	High fever, lethargy, lymphadenopathy, splenomegaly, thrombocytopaenia, epistaxis, petechiae
Sub-clinical	Mild thrombocytopaenia, patient appears clinically well
Chronic (severe)	Pancytopaenia, bone marrow aplasia, bleeding diathesis, weight loss, ocular lesions (uveitis, hyphaema), neurological signs (ataxia, seizures), polyarthritis (A. phagocytophilum)

Treatment Protocol - DOGS AND CATS

Drug	Dose	Route	Interval	Duration	Notes
Doxycycline (drug of choice)	10 mg/kg	PO or IV	q24h (or 5 mg/kg q12h)	Minimum 4 weeks (28 days)	Rapid clinical improvement within 24-48h. Avoid in puppies < 6 months (tooth staining). Give with food.
Minocycline	5-12.5 mg/kg	PO	q12h	4 weeks	Alternative tetracycline
Rifampicin/Rifampin	10-20 mg/kg	PO	q12h	3-4 weeks	May help in experimental ehrlichiosis; not reliably curative
Chloramphenicol	15-25 mg/kg	PO	q8h	4 weeks	Used in dogs < 6 months (avoid doxycycline); monitor for bone marrow suppression

Note: Clinical improvement expected within 24-48 hours of starting doxycycline. If no improvement in 48 hours, reconsider diagnosis. Cats with anaplasmosis respond equally well to doxycycline 10 mg/kg PO q24h x 28 days. (ESCCAP Guideline 2024)

Supportive Care

Blood/platelet transfusion for severe haemorrhage
Avoid glucocorticoids unless concurrent IMHA is confirmed (may worsen infection)
Treat secondary infections if present

3. HEPATOZOONOSIS

Causative Agents

Dogs: Hepatozoon canis (tick ingestion - Rhipicephalus spp.) and Hepatozoon americanum (USA - Amblyomma maculatum)
Cats: Hepatozoon felis (usually subclinical)

Signs and Symptoms

Species/Organism	Clinical Signs
H. canis (mild-moderate)	Lethargy, weight loss, lymphadenopathy, anaemia, mild fever
H. americanum (severe)	Marked pain on palpation, muscle wasting, periosteal bone proliferation (pathognomonic), severe cachexia, purulent ocular discharge, cyclic fever
Cats (H. felis)	Usually subclinical; mild anaemia occasionally

Treatment Protocol - DOGS

H. canis:

Drug	Dose	Route	Interval	Duration
Imidocarb dipropionate	5 mg/kg	IM or SC	2 weeks apart	2-4 doses
Doxycycline	10 mg/kg	PO	q24h	3-4 weeks
Toltrazuril	5-10 mg/kg	PO	q24h	5-7 days

H. americanum (TABS Protocol - Triple combination):

Drug	Dose	Route	Interval	Duration
Trimethoprim-sulfadiazine	15 mg/kg	PO	q12h	14 days (induction)
Pyrimethamine	0.25 mg/kg	PO	q24h	14 days (induction)
Clindamycin	10 mg/kg	PO	q8h	14 days (induction)
Maintenance: Decoquinate	10-20 mg/kg	PO mixed with food	q12h	Lifelong (prevents relapse)

Decoquinate (Deccox) maintenance is critical for H. americanum - discontinuation leads to relapse in most dogs.

4. CYTAUXZOONOSIS (CATS ONLY)

Causative Agent

Cytauxzoon felis - USA (South-central and Southeast); transmitted by Amblyomma americanum and Dermacentor variabilis. Previously almost 100% fatal; survival possible with aggressive treatment.

Signs and Symptoms

Rapid onset: high fever (40-41.5°C), profound lethargy, anorexia
Pale/icteric mucous membranes
Dyspnoea, tachypnoea
Tachycardia, hypothermia (terminal)
Icterus, hepatosplenomegaly
Death within 1-5 days if untreated

Treatment Protocol - CATS

Drug	Dose	Route	Interval	Duration	Notes
Atovaquone + Azithromycin (preferred combination)	15 mg/kg + 10 mg/kg	PO with fatty meal + PO	q8h + q24h	10 days	Best survival rates (60% vs 25% with supportive only); give together
Imidocarb dipropionate (adjunct)	2 mg/kg	IM	Once	-	Some protocols combine with atovaquone
Heparin	200-300 IU/kg	SC	q6-8h	During hospitalisation	For prevention/treatment of thromboembolic disease

Supportive Care (Intensive - essential for survival)

IV fluid therapy (avoid over-hydration; monitor for pulmonary oedema)
Nutritional support (nasogastric tube if not eating)
NSAIDs - Meloxicam 0.1 mg/cat SC/PO q24h for fever/pain
Anti-nausea: Maropitant 1 mg/kg SC q24h
Blood transfusion if PCV < 12%
Broad-spectrum antibiotics for secondary infections

5. LEISHMANIOSIS (DOGS - Leishmania infantum)

Signs and Symptoms

Skin lesions: alopecia, scaling, hyperkeratosis (nose/footpads), nodules, ulcers
Lymphadenopathy (generalised)
Weight loss and muscle atrophy (cachexia)
Epistaxis, polyuria/polydipsia (renal involvement)
Ocular lesions (uveitis, keratoconjunctivitis)
Splenomegaly and hepatomegaly
Lameness (polyarthritis)

Treatment Protocol - DOGS

Drug	Dose	Route	Interval	Duration	Notes
Meglumine antimoniate	50 mg/kg	SC	BID (q12h)	4-6 weeks	First-line; combine with allopurinol
Allopurinol	10 mg/kg	PO	BID (q12h)	6-18 months	Maintenance/secondary prevention; continues after antimoniate stopped
Miltefosine	2 mg/kg	PO with food	q24h	28 days	Oral alternative to antimoniate; teratogenic - use with caution
Meglumine antimoniate + Allopurinol	See above	Combined	-	Combined protocol	Most effective combination; standard of care in endemic areas

Leishmaniosis is not curable - treatment achieves clinical remission and reduces parasite burden. Lifelong monitoring with serology and PCR is recommended. (ESCCAP 2024)

Cats with Leishmaniosis: Allopurinol 10-15 mg/kg PO BID for several months is most frequently used. Limited pharmacokinetic data available in cats.

6. HAEMOPLASMOSIS (Mycoplasma haemofelis / Haemobartonellosis)

Causative Agents

Cats: Mycoplasma haemofelis (most pathogenic), 'Candidatus M. haemominutum', 'Candidatus M. turicensis'
Dogs: Mycoplasma haemocanis (mainly in splenectomised/immunosuppressed dogs)

Signs and Symptoms

Acute haemolytic anaemia: pale/white mucous membranes, tachycardia, tachypnoea
Lethargy, weakness, collapse
Icterus (jaundice)
Splenomegaly
Cyclic fever
Anorexia, weight loss
Dogs: often subclinical unless immunocompromised or splenectomised

Treatment Protocol - CATS AND DOGS

Drug	Dose	Route	Interval	Duration	Notes
Doxycycline (drug of choice)	5-10 mg/kg	PO or IV	q12h-q24h	Minimum 4 weeks (some recommend 8 weeks for cats)	Reduces parasitaemia, improves clinical signs; may not fully eliminate organism; give with food/water to prevent oesophageal stricture in cats
Marbofloxacin (alternative)	2-2.5 mg/kg	PO	q24h	3-4 weeks	Fluoroquinolone alternative
Pradofloxacin	5 mg/kg	PO	q24h	3-4 weeks	Licensed for cats in some countries
Enrofloxacin	5 mg/kg	PO	q24h	3-4 weeks	Caution in cats - risk of retinal toxicity at higher doses; use with care

Supportive Care

Prednisolone 1-2 mg/kg PO q24h if concurrent IMHA (titrate down over 4-8 weeks)
Blood transfusion if PCV < 12% cats or < 15% dogs
Syringe/assisted feeding if anorexic
Treat underlying immunosuppression (e.g., FIV/FeLV in cats)

7. TRYPANOSOMOSIS

Causative Agents

Trypanosoma cruzi (Chagas disease) - dogs, cats; Americas
Trypanosoma brucei (Sleeping sickness) - dogs; Africa (rare in pets)
Trypanosoma evansi (Surra) - dogs; Asia, Africa, South America

Signs and Symptoms

Phase (T. cruzi)	Signs
Acute	Fever, lymphadenopathy, oedema, myocarditis, sudden death (young dogs)
Indeterminate	Subclinical
Chronic	Dilated cardiomyopathy, arrhythmias, CHF signs: ascites, pleural effusion, exercise intolerance

Treatment Protocol - DOGS (T. cruzi)

Drug	Dose	Route	Interval	Duration	Notes
Benznidazole (drug of choice)	5-7 mg/kg	PO	q12h	60 days	Most effective in acute phase; poor efficacy in chronic phase; monitor for GI/neurological side effects
Nifurtimox	2-7 mg/kg	PO	q8h	3-4 months	Alternative; not widely available; causes GI side effects

Note: Treatment efficacy for T. cruzi is limited and largely ineffective in the chronic cardiac phase. Cardiac management (antiarrhythmics, ACE inhibitors) becomes the focus.

T. evansi (Surra):

Drug	Dose	Route	Interval
Diminazene aceturate	3.5-7 mg/kg	IM	Single dose, repeat if needed
Isometamidium chloride	0.5-1 mg/kg	IM	Single dose

Summary Reference Table: Key Drugs at a Glance

Drug	Disease	Dogs Dose	Cat Dose	Route
Imidocarb dipropionate	Babesiosis, Hepatozoonosis, Ehrlichiosis	5-6 mg/kg x2 (2 wks apart)	5 mg/kg x2	IM/SC
Atovaquone + Azithromycin	B. gibsoni, Cytauxzoonosis	13.5 + 10 mg/kg	15 + 10 mg/kg	PO q8h + q24h x10d
Primaquine phosphate	Babesiosis (B. felis)	-	0.5 mg/kg q72h x3 then weekly x3	PO/IM
Diminazene aceturate	Babesiosis, Trypanosomosis	3.5-7.5 mg/kg	2-3 mg/kg	IM
Doxycycline	Ehrlichiosis, Anaplasmosis, Haemoplasmosis	10 mg/kg q24h x28d	5-10 mg/kg q12-24h x28d+	PO/IV
Meglumine antimoniate	Leishmaniosis	50 mg/kg BID x4-6 wks	Limited data	SC
Allopurinol	Leishmaniosis (maintenance)	10 mg/kg BID x6-18 months	10-15 mg/kg BID	PO
Clindamycin + TMP-SDZ + Pyrimethamine	H. americanum	See TABS protocol above	-	PO
Benznidazole	T. cruzi	5-7 mg/kg q12h x60d	Same	PO

General Principles of Management

Diagnosis first - blood smear (Giemsa stain), PCR, serology, CBC, biochemistry before starting treatment
Supportive care is as important as antiprotozoal therapy - especially fluids, blood transfusions, and nutritional support
Vector control (tick/flea prevention) is mandatory to prevent reinfection and transmission to humans (zoonotic risk for Babesia, Leishmania, T. cruzi)
Recheck PCR/serology at 1-3 months post-treatment to assess response
Co-infections are common (e.g., Ehrlichia + Babesia) - screen for multiple pathogens in tick-endemic areas
Pre-treat with atropine (0.05 mg/kg SC) before every imidocarb injection to prevent cholinergic crisis

Key reference: ESCCAP Guideline GL5 - Control of Vector-Borne Diseases in Dogs and Cats (December 2024) - this is the most current comprehensive guideline available.

Generate a clinical decision tree for diagnosing co-infections in dogs and cats

Generating Image

A detailed veterinary clinical decision tree diagram for diagnosing haemoprotozal co-infections in dogs and cats. The flowchart starts at the top with "Febrile/Ill Dog or Cat with Tick/Vector Exposure History" and branches down through multiple decision nodes. Include the following flow: Node 1 (Start): "Febrile/Anaemic/Thrombocytopenic Dog or Cat - Tick or Vector Exposure?" → YES branch continues down → NO branch: "Consider non-vector-borne differentials" Node 2: "Perform Initial Diagnostics: CBC, Blood Smear (Giemsa), Biochemistry, Urinalysis" Node 3: Splits into DOG and CAT pathways side by side DOG pathway nodes: - "Anaemia + Thrombocytopaenia + Intraerythrocytic organisms on smear?" → Babesia canis/gibsoni - "Thrombocytopaenia + Morulae in monocytes/neutrophils?" → Ehrlichia/Anaplasma - "Severe myalgia + periosteal bone reaction?" → Hepatozoon americanum - "Lymphadenopathy + skin lesions + renal involvement?" → Leishmania CAT pathway nodes: - "Severe haemolytic anaemia + intraerythrocytic organisms?" → Babesia felis / Mycoplasma haemofelis - "Mild anaemia + thrombocytopaenia + tick exposure?" → Anaplasma phagocytophilum - "Acute fever + dyspnoea + rapid deterioration?" → Cytauxzoon felis CO-INFECTION DETECTION node at the bottom: "If poor response to single-agent therapy after 48h → Suspect Co-infection → Run PCR Panel for all pathogens + Serology" Final boxes: "Tailor combination therapy" with arrows pointing back up Use a clean medical infographic style with a white background, color-coded boxes (blue for dogs, orange for cats, red for co-infection node, green for diagnostic steps, yellow for treatment), clear arrows, and professional veterinary clinical typography. Include a legend at the bottom.

Clinical Decision Tree - Haemoprotozal Co-infections in Dogs and Cats

Here is a written breakdown of the full decision logic to use alongside the diagram:

Clinical Decision Tree: Diagnosing Haemoprotozal Co-infections in Dogs and Cats

STEP 1 - Entry Criteria

Any dog or cat presenting with:

Fever (>39.5°C)
Lethargy + anorexia
Pale/icteric mucous membranes
Unexplained anaemia or thrombocytopaenia
Tick/flea/sandfly/triatomine bug exposure history

↓ Proceed to initial diagnostics

STEP 2 - Initial Diagnostics (All Cases)

Run simultaneously:

CBC - look for anaemia (PCV), thrombocytopaenia, leucopaenia/leucocytosis
Blood smear (Giemsa stain) - intraerythrocytic organisms, morulae, RBC morphology
Serum biochemistry - ALT, ALP, creatinine, BUN, bilirubin, total protein
Urinalysis - haemoglobinuria, bilirubinuria, proteinuria (leishmania)
Tick burden assessment - species ID if possible (guides likely pathogens)

STEP 3A - DOG Pathway

Finding on Initial Screen	Suspect	Confirm With
Haemolytic anaemia + intraerythrocytic piriform/ring organisms + thrombocytopaenia	Babesia canis / B. gibsoni	PCR (differentiates species), IFA serology
Thrombocytopaenia + morulae in monocytes/lymphocytes + fever	Ehrlichia canis (CME)	PCR, IFA serology ≥1:80
Thrombocytopaenia + morulae in neutrophils + joint pain	Anaplasma phagocytophilum	PCR, IFA serology
Severe muscle pain + hyperaesthesia + periosteal bone proliferation on X-ray	Hepatozoon americanum	Muscle biopsy (cysts), PCR
Lymphadenopathy + progressive weight loss + skin scaling + proteinuria	Leishmania infantum	Cytology, PCR, IFAT serology ≥1:160
Pale mucous membranes + epiphora + splenomegaly - splenectomised or immunosuppressed	Mycoplasma haemocanis	PCR (blood smear often negative)

STEP 3B - CAT Pathway

Finding on Initial Screen	Suspect	Confirm With
Severe haemolytic anaemia (PCV < 15%) + intraerythrocytic organisms + S. Africa / endemic region	Babesia felis	PCR, blood smear
Moderate anaemia + organisms on RBC surface/within cells + FIV/FeLV positive	Mycoplasma haemofelis	PCR (most sensitive; smear often missed)
Acute: high fever + dyspnoea + rapid collapse + S-central USA	Cytauxzoon felis	Blood smear (piroplasms in RBCs + large schizonts in macrophages), PCR
Thrombocytopaenia + fever + joint swelling	Anaplasma phagocytophilum	PCR, serology
Subclinical anaemia + mild thrombocytopaenia (incidental)	Babesia vogeli / Hepatozoon felis	PCR (serology unreliable)

STEP 4 - Co-infection Detection Gate

Trigger this step when ANY of the following occur:

Poor or incomplete response to single-agent therapy after 48-72 hours
Initial CBC shows multiple-lineage cytopaenias (anaemia + thrombocytopaenia + neutropaenia)
Blood smear shows organisms of different morphology simultaneously
Patient is from a highly tick-endemic area (Mediterranean, SE Asia, USA South)
Concurrent systemic signs not explained by one diagnosis (e.g., renal failure + haemolysis + joint pain)

Action: Run a full PCR multiplex panel targeting all regionally relevant pathogens simultaneously.

STEP 5 - Common Co-infection Combinations

Co-infection Pair	Region	Clinical Clue
Ehrlichia canis + Babesia canis	Global (tropics/subtropics)	Severe pancytopaenia + haemolysis; poor response to doxycycline alone
E. canis + Leishmania infantum	Mediterranean, S. America	Thrombocytopaenia + skin lesions + chronic wasting
Babesia gibsoni + Ehrlichia/Anaplasma	SE Asia, USA	Refractory anaemia + thrombocytopaenia
M. haemofelis + FIV/FeLV	Worldwide (cats)	Non-regenerative anaemia, immunosuppression
C. felis + M. haemofelis	USA South (cats)	Acute collapse + haemolysis in cat from endemic area
Babesia + Hepatozoon (dogs)	Africa, Middle East	Fever + myalgia + anaemia

STEP 6 - Treatment Tailoring for Co-infections

Co-infection	Combined Treatment
E. canis + B. canis	Doxycycline 10 mg/kg q24h x 28d + Imidocarb dipropionate 6 mg/kg IM x 2 doses
Ehrlichia + Leishmania	Doxycycline + Meglumine antimoniate + Allopurinol
B. gibsoni + Ehrlichia	Atovaquone + Azithromycin (10d) + Doxycycline (28d)
M. haemofelis + FIV/FeLV	Doxycycline + Prednisolone (if IMHA) + manage retroviral disease
C. felis + M. haemofelis (cats)	Atovaquone + Azithromycin + Doxycycline + intensive supportive care

Key Rule of Thumb

"In tick-endemic areas, never assume a single pathogen. If the patient does not improve in 48 hours, broaden the diagnostic net with PCR and broaden the treatment to cover the most likely co-infecting organisms."

This is a shared conversation. Sign in to Orris to start your own chat.